Searchable abstracts of presentations at key conferences in endocrinology

ea0063p266 | Pituitary and Neuroendocrinology 1 | ECE2019

Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH and GH-secreting pituitary adenoma cell lines

Fanciulli Alessandro , Gesmundo Iacopo , Gamba Giacomo , Castano Justo P , Luque Raul M , Alvarez Clara V , Dieguez Carlos , Chiara Zatelli Maria , Ghigo Ezio , Schally Andrew V , Granata Riccarda

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETs can be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH) PitNETs. Surgical resection is the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are p...

ea0070aep683 | Pituitary and Neuroendocrinology | ECE2020

Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH- and GH-secreting pituitary neuroendocrine tumor cell lines

Fanciulli Alessandro , Gesmundo Iacopo , Gamba Giacomo , Maria Clara Alvarez Villamarin , Dieguez Carlos , Zatelli Chiara , Cannavò Salvatore , Grottoli Silvia , Arvat Emanuela , Castaño Justo P. , Luque Raùl M. , Cai Renzhi , Sha Wei , Victor Schally Andrew , Granata Riccarda

Pituitary neuroendocrine tumors (PitNETs) are mostly benign lesions originating from the anterior pituitary and represent 10–15% of all the intracranial neoplasms. PitNETscan be classified in non-secretory, clinically non-functioning pituitary adenomas (NFPAs), and secretory, comprising prolactin (PRL), growth hormone (GH) and adrenocoticotropic hormone (ACTH) PitNETs. Surgical resectionis the first line treatment for PitNETs, whereas chemotherapy and radiotherapy are pr...